Latest Pharma and Biotech News
Pharmaceutical
16 April 2026 In what looks to be the largest follow-on stock offering in biopharma history, US oncology company Revolution Medicines priced 10.56 million shares to raise $1.5 billion and $500 million in convertible senior notes due 2033.
Today's issue
Refine search
Pharmaceutical
Revolution Medicines today announced positive top-line results from its global, randomized, controlled Phase III RASolute 302 clinical trial evaluating daraxonrasib in patients with metastatic pancreatic ductal adenocarcinoma (PDAC) who had been previously treated. 13 April 2026
Generics
The Russian Ministry of Health has begun more active cancelling of tenders for drug procurements, waiting for the launch of cheaper generics, as the federal budget experiences a shortage of funds for procurements of expensive original drugs. 13 April 2026
Pharmaceutical
Lotte Bjerre Knudsen, chief scientific advisor to the chief scientific officer, vice president of innovation and data experimentation advancement (IDEA) at Danish pharma major Novo Nordisk, is to leave the company after 36 years. 13 April 2026
Biotechnology
UK pharma major GSK has announced positive findings from its global Phase I BEHOLD-1 clinical trial for mocertatug rezetecan (or Mo-Rez for short), a novel antibody-drug conjugate (ADC) targeting the B7-H4 antigen. 13 April 2026
Pharmaceutical
A new national project will develop a common information structure for clinical trials in Sweden. 13 April 2026
Pharmaceutical
US pharma major Eli Lilly is accelerating manufacturing investment across Asia as the scramble to secure supply of high-demand GLP-1 therapies intensifies. 13 April 2026
Pharmaceutical
Today, AstraZeneca announced that Lokelma (sodium zirconium cyclosilicate; SZC) has received a draft recommendation by the UK’s National Institute for Health and Care Excellence (NICE), broadening access for the treatment of hyperkalemia. 13 April 2026
Biotechnology
Chinese clinical-stage biotech OriCell Therapeutics announced the cumulative closing of a pre-initial public offering (IPO) financing round in excess of $110 million. 13 April 2026
Biotechnology
The European Commission has approved Dupixent (dupilumab) for the treatment of moderate-to-severe chronic spontaneous urticaria (CSU) in children aged two to 11 years with inadequate response to histamine-1 antihistamines (H1AH) and who are naïve to anti-immunoglobulin E (IgE) therapy for CSU. 13 April 2026
Pharmaceutical
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted approval for German pharma major Bayer’s Kerendia (finerenone) in a new indication. 13 April 2026
Biotechnology
US biotech Replimune has suffered a fresh blow after the US Food and Drug Administration rejected its lead cancer therapy RP1 (vusolimogene oderparepvec), sending shares sharply lower and casting doubt over the program’s future. 13 April 2026
Pharmaceutical
China/US biotech Vivatides Therapeutics has secured $54 million in an oversubscribed series A round, less than a year after launch, as it looks to break one of RNA medicine’s key constraints: delivery beyond the liver. 13 April 2026
Pharmaceutical
Greek industry body the Hellenic Association of Pharmaceutical Companies (SFEE) has criticized the government’s latest plan to offset pharmaceutical clawback liabilities against research and development (R&D) and investment spending for 2026–2027, arguing it fails to support clinical trial activity. 13 April 2026
Pharmaceutical
The last week produced a fairly concentrated set of human-medicines updates, with the clearest approval activity coming from the UK's Medicines and Healthcare products Regulatory Agency, the Therapeutic Goods Administration in Australia and Brazil’s Agência Nacional de Vigilância Sanitária. 13 April 2026
Pharmaceutical
The number of drug launches in Europe has fallen by around 35% in the 10 months since the USA introduced a new drug pricing policy, according to an analysis by the international research agency GlobalData. The figures are serious for European patients, says the Danish pharma trade group Lif. 13 April 2026
Pharmaceutical
India’s push to expand global trade through Free Trade Agreements (FTAs) is opening up significant opportunities for the pharmaceutical, healthcare and medical technology sectors. 13 April 2026
Biotechnology
Important news last week kicked off with Neurocrine Biosciences announcing a proposed $2.9 billion takeover bid for Solena Therapeutics. Then Gilead Sciences revealed an up to $5 billion takeover for German antibody-drug conjugate (ADCs) developer Tubulis. Also of note, Sanofi released mixed Phase II results for its asthma and dermatology candidate lunsekimig. The US Food and Drug Administration (FDA) announced plans for greater control of direct-to-consumer Rx medicines advertising. 12 April 2026
Biotechnology
German biotech BioNTech today announced positive results from the primary analysis of a Phase II cohort evaluating trastuzumab pamirtecan (BNT323/DB-1303) in patients with HER2-expressing, advanced endometrial cancer whose disease progressed on or after first-line chemotherapy with or without prior checkpoint inhibitor treatment. 11 April 2026
Pharmaceutical
The UK’S Medicines and Healthcare products Regulatory Agency (MHRA) has approved Swedish Orphan Biovitrum Tryngolza (olezarsen) to help treat adults with familial chylomicronemia syndrome (FCS). 11 April 2026
Pharmaceutical
German pharma Boehringer Ingelheim has handed full commercial and marketing rights for digital schizophrenia therapy CT-155 to US-based Click Therapeutics, reshaping a partnership first struck in 2020. 10 April 2026
All news
Biotechnology
Genetic medicines company MeiraGTx Holdings has reacquired global rights to its Phase III gene therapy candidate for X-linked retinitis pigmentosa (XLRP), botaretigene sparoparvovec (bota-vec), from Johnson & Johnson, and priced a $100 million public offering of ordinary shares to support advancement of its late-stage pipeline. 16 April 2026
Biotechnology
Oxford, UK-based Alethio Therapeutics, a biopharmaceutical company developing novel treatments for myeloproliferative neoplasms (MPN), today announced the unveiling of ATX 011, a first in class, mutation agnostic antibody with potential to disrupt the $2 billion essential thrombocythemia (ET) market. 16 April 2026
Pharmaceutical
US health technology assessor the Institute for Clinical and Economic Review (ICER), in collaboration with Verdant Research, has published a new white paper that examines the evolution – and perception – of the Food and Drug Administration (FDA) accelerated approval pathway. 16 April 2026
Pharmaceutical
Japanese drugmaker Daiichi Sankyo says it has agreed to transfer all of its shares in Daiichi Sankyo Healthcare (DSHC), a consolidated subsidiary of the company, to Suntory Holdings and today entered into a stock transfer agreement with Suntory HD. 16 April 2026
Biosimilars
Japanese drugmaker Mochida Pharmaceutical announces that it has entered into an agreement with Qilu Pharmaceutical regarding the development and commercialization in Japan of Qilu’s biosimilar of follitropin alfa (genetical recombination). 16 April 2026
Biotechnology
US biotech Terremoto Biosciences, a firm developing highly-targeted small molecule medicines, has announced the closing of a $108 million Series C financing round. 16 April 2026
Biotechnology
UK-based STORM Therapeutics, a biotech targeting RNA modifications to reprogram cells and develop novel cancer therapies, has announced a successful $56 million Series C financing. 16 April 2026
Pharmaceutical
USA-based SQ Innovation has struck a long-term supply agreement with Italian active pharmaceutical ingredient (API) specialist FIS to secure pharmaceutical-grade furosemide for its marketed product Lasix ONYU and future pipeline assets. 16 April 2026
Pharmaceutical
US-based Sonire Therapeutics has secured $18 million in Series A financing to advance clinical development of its non-invasive cancer therapy, with a focus on pancreatic cancer. The round was led by Santé Ventures, with participation from Fast Track Initiative, Nomura SPARX Investment and SBI Investment. 16 April 2026
Pharmaceutical
In what looks to be the largest follow-on stock offering in biopharma history, US oncology company Revolution Medicines priced 10.56 million shares to raise $1.5 billion and $500 million in convertible senior notes due 2033. 16 April 2026
Pharmaceutical
The US Food and Drug Administration will ask outside advisers in July whether some peptide substances should be allowed on the 503A Bulks List, a step that could reopen debate over compounded products now popular in wellness and performance circles. 16 April 2026
Biotechnology
German innovation hub BioMed X has launched its first research team in France, partnering with French pharma Servier to advance AI-driven antibody engineering at the Paris-Saclay campus. 16 April 2026
Pharmaceutical
German drugmaker Bayer has highlighted publication of full results from its Phase III OCEANIC-STROKE trial in the New England Journal of Medicine, adding weight to its case for the investigational anticoagulant asundexian. 16 April 2026
Pharmaceutical
UK-based specialty pharma company CNX Therapeutics today announced the appointment of David Flint as chief corporate development officer (CCDO), effective April 7, 2026. 16 April 2026
Biotechnology
Privately-held Swiss drug firm Ewopharma has reported that sugemalimab, licensed from Chinese partner CStone Pharmaceuticals, has received I, A recommendation in the European Society for Medical Oncology (ESMO) Early and Locally Advanced Non-Small-Cell Lung Cancer Living Guideline. 16 April 2026
Pharmaceutical
New research from researchers at the University of Florida, University of Maryland and Yale School of Public Health has found that if measles, mumps and rubella (MMR) immunization rates continue to fall, even by just a percentage point, measles could re-establish itself as an endemic disease in the USA within years. 16 April 2026
Biotechnology
Enodia Therapeutics, a privately-held French biotech developing small molecule therapies targeting a unique form of protein degradation at the point of synthesis, has appointed Yvonne McGrath as chief scientific officer (CSO). 15 April 2026
Biotechnology
US clinical-stage biotechnology company Beeline Medicines today announced its official debut with the mission of developing and delivering category-leading precision therapies to transform the lives of people with autoimmune and inflammatory diseases. 15 April 2026
Pharmaceutical
Johnson & Johnson has announced its financial results for the first quarter of 2026. 15 April 2026
Pharmaceutical
Danish allergy immunotherapy specialist ALK Abello today announced that Health Canada has approved Neffy 2mg adrenaline (epinephrine) nasal spray for the emergency treatment of allergic reactions (anaphylaxis) due to insect stings or bites, foods, medicinal products and other allergens, as well as idiopathic or exercise-induced anaphylaxis in adult and paediatric patients (≥30 kg). 15 April 2026
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze